or Try an Advanced Search...

    Technical Analysis for LEGN - Legend Biotech Corporation

    Grade Last Price % Change Price Change
    F 45.17 -4.81% -2.28
    LEGN closed down 4.81 percent on Wednesday, April 24, 2024, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 13
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical LEGN trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    New 52 Week Low Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup -4.81%
    Lower Bollinger Band Walk Weakness -4.81%
    Oversold Stochastic Weakness -4.81%
    Older End-of-Day Signals for LEGN ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 6 hours ago
    New 52 Week Low about 7 hours ago
    Lower Bollinger Band Support about 8 hours ago
    Outside Day about 8 hours ago
    Slingshot Bearish Entry about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    LEGN Chart by TradingView
    Basic chart:

    Profile

    Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Life Sciences Cell Therapy Genscript Biotech Tax Investigation

    Is LEGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Apr 17 Scotiabank upgrades Legend Biotech to sector outperform
    Apr 17 Analyst Ratings For Legend Biotech
    Apr 11 Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
    Apr 8 FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
    Apr 8 Why Legend Biotech (LEGN) Stock Might be a Great Pick
    Apr 6 Johnson & Johnson wins FDA nod for Carvykti label expansion
    Apr 6 Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
    Apr 3 Should You Continue to Hold Legend Biotech Corporation (LEGN)?
    Mar 29 Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4
    See more LEGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 77.32
    52 Week Low 45.12
    Average Volume 1,004,178
    200-Day Moving Average 63.20
    50-Day Moving Average 58.61
    20-Day Moving Average 52.57
    10-Day Moving Average 49.16
    Average True Range 2.37
    RSI (14) 23.08
    ADX 33.58
    +DI 12.52
    -DI 26.36
    Chandelier Exit (Long, 3 ATRs) 52.44
    Chandelier Exit (Short, 3 ATRs) 52.22
    Upper Bollinger Bands 60.70
    Lower Bollinger Band 44.43
    Percent B (%b) 0.05
    BandWidth 30.96
    MACD Line -3.61
    MACD Signal Line -2.99
    MACD Histogram -0.6195
    Fundamentals Value
    Market Cap 8.23 Billion
    Num Shares 182 Million
    EPS -2.96
    Price-to-Earnings (P/E) Ratio -15.26
    Price-to-Sales 47.00
    Price-to-Book 8.30
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 50.32
    Resistance 3 (R3) 50.87 49.71 49.46
    Resistance 2 (R2) 49.71 48.40 49.43 49.17
    Resistance 1 (R1) 47.44 47.59 46.86 46.89 48.89
    Pivot Point 46.28 46.28 45.99 46.00 46.28
    Support 1 (S1) 44.01 44.97 43.43 43.46 41.45
    Support 2 (S2) 42.85 44.16 42.57 41.17
    Support 3 (S3) 40.58 42.85 40.88
    Support 4 (S4) 40.03